US-based medical device company Hologic has unveiled the MyoSure Reach device to address issues of hard-to-reach uterine pathology.
A part of Hologic’s MyoSure suite of gynecologic surgical products, the new device enables physicians to reach the upper third of the uterine cavity which is considered as an otherwise inaccessible area to be treated.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Hologic medical affairs medical director and vice-president Edward Evantash said: "The ability to remove hard-to-reach intrauterine pathology is an important enhancement for the MyoSure system, and it demonstrates Hologic’s dedication to women’s health.
"The MyoSure Reach device offers the benefits of the current device, plus expanded capabilities to remove pathology in the upper third of the uterine cavity."
The MyoSure tissue removal system will offer a simple and fast solution for women with polyps and fibroids, which often lead to abnormal uterine bleeding (AUB).
It is reported that about 11% to 13% of reproductive-age women and nearly 24% of women aged 36 to 40 are said to be affected by AUB and experience heavy bleeding during their menstruation before they reach menopause.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe device is composed of stainless steel, characterised with extra hardness and high-wear resistance.
It features a shortened distance from the distal tip to the cutting window of less than 1mm which facilitates closer access to the polyps and fibroids up to 3cm
While resecting tissue simulated in the upper region of the uterine cavity, the Myosure Reach device gets three times closer to the uterine model wall and removes 25% more tissue in the simulated bench top model.
